Degroof Petercam Initiates Coverage of Oncodesign Precision Medicine
19 4월 2024 - 1:00AM
Business Wire
Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63;
Mnemonic: ALOPM), a biopharmaceutical company specializing in
precision medicine for the treatment of resistant and metastatic
cancer, today announced that Degroof Petercam, a brokerage firm and
investment bank, has initiated coverage of its shares.
In its initiation study entitled “Targeted therapies for
inflammation & oncology”, Degroof Petercam began covering the
stock by rendering its first commissioned research report on the
Company with a €1.90-€2.70 target price range1.
About Oncodesign Precision Medicine (OPM)
Oncodesign Precision Medicine (OPM), founded in 2022, is a
biopharmaceutical company specializing in precision medicine,
dedicated to the discovery of treatments for resistant and
metastatic cancers.
OPM currently has two kinase inhibitors in clinical trials:
OPM-101, for the treatment of chronic immuno-inflammatory digestive
diseases, which demonstrated a significant therapeutic margin and
lack of toxicity in phase I trials with healthy volunteers, with a
phase II trials in cancer patients with severe colitis induced by
treatment with immuno checkpoint inhibitors (CUII) scheduled to
start at the end of 2024. OPM-201, licensed to Servier for the
treatment of Parkinson's disease, completed its phase I trial in
healthy volunteers this year, with phase II scheduled to start in
2025. Finally, a third kinase inhibitor, OPM-102, targeting
oncology, is in preclinical development.
These three molecules come from the Nanocyclix® technology
platform, which enables the design and selection of small
macrocyclic kinase inhibitors that are highly effective and
selective. We now have 12,000 molecules in our library and will be
using AI to accelerate the discovery of drug candidates while
reducing the cost of this phase.
OPM's two other technology platforms are:
- OncoSNIPER, for the selection of therapeutic targets using
artificial intelligence, in partnership with Servier for the search
of targets in pancreatic cancer,
- PROMETHE® for the design and selection of radiolabeled
biological molecules for systemic radiotherapy, for which we are
currently discussing partnerships with vectorization
companies.
OPM, co-founded by Philippe Genne, Jan Hoflack and Karine
Lignel, is based in Dijon, in the heart of the university and
hospital cluster, and has 22 employees.
Further information: oncodesign.com
1 This information does not constitute an offer to sell or
subscribe, or the solicitation of an order to buy or subscribe,
securities in France, Europe, the United States or any other
country. The coverage is commissioned research, meaning it has been
agreed upon between Oncodesign Precision Medicine and Degroof
Petercam whereby the company has appointed DP to cover the company
and is paying for this service.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240418463364/en/
OPM Karine Lignel Deputy General Manager Tel: +33 (0)3 80
78 41 93 investisseurs@oncodesign.com
NewCap Investor Relations Mathilde Bohin / Alban Dufumier
Tel: +33 (0)1 44 71 94 95 oncodesign@newcap.eu
NewCap Media Relations Arthur Rouillé Tel: +33 (0)1 44 71
00 15 oncodesign@newcap.eu
Oncodesign Precision Med... (EU:ALOPM)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Oncodesign Precision Med... (EU:ALOPM)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
